BioAtla (NASDAQ:BCAB) Upgraded at Wall Street Zen

BioAtla (NASDAQ:BCAB) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

BCAB has been the topic of a number of other research reports. Rodman & Renshaw assumed coverage on shares of BioAtla in a research note on Tuesday, January 13th. They set a “buy” rating and a $200.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioAtla in a report on Friday, January 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, BioAtla presently has a consensus rating of “Hold” and an average price target of $200.00.

BioAtla Trading Down 1.3%

Shares of BioAtla stock opened at $4.46 on Friday. The company has a 50 day moving average of $8.28 and a 200-day moving average of $24.96. BioAtla has a 1-year low of $3.92 and a 1-year high of $71.50. The company has a market cap of $5.66 million, a PE ratio of -0.09 and a beta of 1.22.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($8.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($18.00) by $10.00. The firm had revenue of $2.00 million during the quarter, compared to the consensus estimate of $0.70 million. Research analysts forecast that BioAtla will post -1.46 earnings per share for the current year.

Institutional Investors Weigh In On BioAtla

Large investors have recently added to or reduced their stakes in the business. Woodline Partners LP bought a new position in BioAtla during the first quarter worth $26,000. Sheets Smith Investment Management bought a new position in BioAtla during the third quarter worth $46,000. ADAR1 Capital Management LLC bought a new position in BioAtla in the fourth quarter worth approximately $104,000. Susquehanna International Group LLP grew its stake in BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after acquiring an additional 177,760 shares during the period. Finally, Jane Street Group LLC increased its holdings in shares of BioAtla by 55.4% during the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after acquiring an additional 123,597 shares in the last quarter. Institutional investors and hedge funds own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.